• Kang Stem Biotech received the Phase 1/2a clinical study report for FURESTEM-OA Kit Inj. in knee osteoarthritis on Oct. 26, 2026.
• Both tested doses significantly improved pain and function versus placebo; joint-structure results were mixed.
• Safety and tolerability were deemed acceptable, despite more drug-related adverse reactions; no serious drug-related reactions or withdrawals occurred.
• The report will support follow-up South Korean trial design and regulatory discussions in collaboration with domestic partner Yuyoung Pharmaceutical.
• Topline results were disclosed July 28, 2026; findings will be used in investor materials, press releases and scientific presentations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kang Stem Biotech Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261026900773), on October 26, 2026, and is solely responsible for the information contained therein.